Pharmalytics Group provides expertise in strategic consulting, health technology assessment, and analytics to support pharmaceutical product commercialization.
Evidence Synthesis
Economic Modelling
Real-World Evidence
Generation
Market Access Strategy
& Analytics
Publications
Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...
The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.
ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine.
On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?
Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and...
Quality of Life in Wilson’s Disease: A Systematic Literature Review.
Can Standard Health Technology Assessment Approaches Help Guide the Price of Orphan Drugs...
The Impact of Digital Therapeutics on Current Health Technology Assessment Frameworks.
Reimbursement and health technology submissions
Agencies
NICE, SMC, IQWiG, NOMA, HAS, CADTH, pCODR
Therapeutic
areas
Peer-reviewed publications